Quetiapina y enfermedad de Parkinson

Tajes Alonso, María; Martínez Formoso, Silvia; Arrojo Romero, Manuel.
Psiquiatr. biol. (Ed. impr.) ; 14(1): 45-45, ene. 2007.
Artículo en Es | IBECS (España) | ID: ibc-053005

Documentos relacionados

  1. L-DOPA-therapy in Parkinson's disease: some personal reflections on L-DOPA therapy from Vienna and Berlin.
  2. The Role of Helicobacter pylori and Small Intestinal Bacterial Overgrowth in Parkinson's Disease.
  3. Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.
  4. Novel insights into the effects of levodopa on the up- and downstrokes of writing sequences.
  5. Interactions of a boron-containing levodopa derivative on D<sub>2</sub> dopamine receptor and its effects in a Parkinson disease model.
  6. Gastrointestinal Motility and Response to Levodopa in Parkinson's Disease: A Proof-of-Concept Study.
  7. Tools and criteria to select patients with advanced Parkinson's disease for device-aided therapies: a narrative review.
  8. Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty.
  9. [The questions of the treatment of Parkinson's disease].
  10. Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson's Disease.